J Cancer Prev 2021; 26(1): 32-40
Published online March 30, 2021
https://doi.org/10.15430/JCP.2021.26.1.32
© Korean Society of Cancer Prevention
Yi-Wen Huang1 ,*, Chien-Wei Lin2
,*, Pan Pan3
,*, Carla Elena Echeveste3
, Athena Dong3
, Kiyoko Oshima4
, Martha Yearsley5
, Jianhua Yu6
,**, Li-Shu Wang3
,**
1Department of Obstetrics & Gynecology, 2Division of Biostatistics, 3Division of Hematology and Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, 4Department of Pathology, Johns Hopkins University, Baltimore, MD, 5Department of Pathology, The Ohio State University, Columbus, OH, 6Department of Hematology and Hematopoietic Cell Transplantation, Comprehensive Cancer Center, City of Hope National Medical Center, Duarte, CA, USA
Correspondence to :
Li-Shu Wang, E-mail: liswang@mcw.edu, https://orcid.org/0000-0002-6500-6943
Jianhua Yu, E-mail: jiayu@coh.org, https://orcid.org/0000-0002-0326-3223
*These authors contributed equally to this work as co-first authors.
**These authors contributed equally to this work as co-correspondence authors.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Free fatty acid receptor 2 (
Keywords: Ffar2, ApcMin/+, Colorectal cancer, Metabolomics, Gut microbiota
Qinglong Liu, Xiaojing Li, Hao Zhang, Haitao Li
J Cancer Prev 2022; 27(1): 31-41 https://doi.org/10.15430/JCP.2022.27.1.31Mizuho Nakayama, Dong Wang, Sau Yee Kok, Hiroko Oshima, Masanobu Oshima
J Cancer Prev 2022; 27(1): 1-6 https://doi.org/10.15430/JCP.2022.27.1.1Bantalem Tilaye Atinafu, Fekadu Aga Bulti, Tefera Mulugeta Demelew
Journal of Cancer Prevention 2020; 25(1): 38-47 https://doi.org/10.15430/JCP.2020.25.1.38